Compare McCormick & Company, Incorporated (MKC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Novo Nordisk A/S — how do they compare? McCormick & Company, Incorporated trades at $52.01 (market cap $14.04B), while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 15.7× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (3.68%). Which is the better fit depends on your goals.
| MKC | NVO | |
|---|---|---|
Market Cap | $14.04B | $220.53B |
Sector | Consumer Staples | Health |
52-Week High | $72.81 | $71.70 |
52-Week Low | $45.60 | $35.29 |
Enterprise Value | $18.65B | $239.49B |
Dividend Yield | 3.68% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $52.35, up 1.26% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong profitability with a 21.91% net margin and 25.7% ROE, supported by recent Q2 2026 earnings beating estimates. Valuation appears attractive with a P/E of 8.69 and P/S of 1.9. The pending Unilever Foods deal, highlighted in recent news (The Motley Fool, 2026-07-07), could transform the business, though organic growth remains modest.
The outlook is cautiously optimistic with 36.7% of analysts rating it Buy and a consensus price target of $59.67 (13.9% upside). Key risks include soft consumer volumes and execution challenges from the Unilever integration. Positive cash flow projections for 2026 and a sustainable dividend enhance appeal, but investors should monitor volume trends and deal progress closely.
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
